Across TCGA pan-cancer cohorts, CYP26B1 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of CYP26B1’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where CYP26B1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CYP26B1 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.
LUAD, LSCC, and CCRCC are the cancer types where CYP26B1 tumor–normal differential expression is most reproducible.